The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry
Open accessAbstract
BACKGROUND: Adults with triple-class refractory (TCR) multiple myeloma (MM) have limited treatment options and poor prognosis, but the burden of TCR MM has not been well characterized. This study evaluated treatment patterns, overall survival (OS), health-related quality of life (HRQoL), and healthcare resource use (HCRU) among patients with TCR MM in US clinical practice. PATIENTS AND METHODS: Patients with TCR MM in the Connect MM Registry (NCT01081028; a large, US, multicenter, prospective observational cohort study of patients with newly diagnosed MM) were included. Patient characteristics, treatment patterns, HRQoL, and HCRU were analyzed using descriptive statistics. OS was calculated using Kaplan-Meier methodology for the overall cohort and for patients with/without ≥1 post-TCR line of therapy (LOT). RESULTS: A total of 232 patients with TCR MM were included; 155 (67%) had ≥1 post-TCR LOT (post-TCR-Treated subgroup; median 9.9 months of follow-up). Most common post-TCR treatments were carfilzomib (47%), pomalidomide (40%), and daratumumab (26%); median treatment duration was 3.3 months. Median OS was 9.9 months in the overall population, 10.8 months in post-TCR-Treated patients, and 2.6 months for those with no new post-TCR LOT. HRQoL deteriorated and pain increased over 1 year of follow-up, with clinically meaningfully changes in EQ-5D (mean, -0.06 points) and FACT-G (mean, -9.9 points). 124 (53%) patients had ≥1 all-cause hospitalization and 58 (25%) had ≥1 MM-related hospitalization; median annualized length of stay was 35.3 and 42.9 days, respectively. CONCLUSION: The burden of TCR MM is substantial, emphasizing the need for more effective treatment options in the TCR setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with triple-class-exposed relapsed and refractory multiple myeloma, conventional therapies yield poor prognosis, with median progression-free survival of approximately 3 to 5 months and median overall survival of approximately 9 to 22 months.
“Prognosis is poor with conventional therapies, with a median progression-free survival (PFS) of ~3 to 5 months and a median overall survival (OS) of ~9 to 22 months in this patient population. 5-12”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [9]
Citations
Cites
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citation
Flagged first, then by citations
Research works printed but not linked: 18
- Kumar, 2014, Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients, Leukemia, 28, 1122, 10.1038/leu.2013.313 · DOI
- Turesson, 2010, Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study, J Clin Oncol, 28, 83, 10.1200/JCO.2009.25.4177 · DOI
- Naymagon, 2016, Novel agents in the treatment of multiple myeloma: a review about the future, J Hematol Oncol, 9, 52, 10.1186/s13045-016-0282-1 · DOI
- Gandhi, 2019, Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy, Leukemia, 33, 2266, 10.1038/s41375-019-0435-7 · DOI · Paper page
- Nijhof, 2018, Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update, Drugs, 78, 19, 10.1007/s40265-017-0841-y · DOI
- Kumar, 2017, Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study, Leukemia, 31, 2443, 10.1038/leu.2017.138 · DOI · Paper page
- Engelhardt, 2021, Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany, Clin Lymphoma Myeloma Leuk, 21, e160, 10.1016/j.clml.2020.10.002 · DOI
- Mikhael, 2020, Treatment options for triple-class refractory multiple myeloma, Clin Lymphoma Myeloma Leuk, 20, 1, 10.1016/j.clml.2019.09.621 · DOI · Paper page
- Despiégel, 2019, Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France, Clin Lymphoma Myeloma Leuk, 19, e13, 10.1016/j.clml.2018.08.019 · DOI
- Kyle, 2009, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, 23, 3, 10.1038/leu.2008.291 · DOI
- Rajkumar, 2015, Guidelines for determination of the number of prior lines of therapy in multiple myeloma, Blood, 126, 921, 10.1182/blood-2015-05-647636 · DOI
- van Hout, 2012, Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets, Value Health, 15, 708, 10.1016/j.jval.2012.02.008 · DOI · Paper page
- Abonour, 2021, Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect MM Registry, Br J Haematol, 193, 93, 10.1111/bjh.17131 · DOI
- King, 2010, Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire, Patient Relat Outcome Meas, 1, 119, 10.2147/PROM.S10621 · DOI
- Pickard, 2007, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer, Health Qual Life Outcomes, 5, 70, 10.1186/1477-7525-5-70 · DOI
- Madduri, 2021, Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA, Future Oncol, 17, 503, 10.2217/fon-2020-1003 · DOI
- Whitney, 2019, Unplanned hospitalization among individuals with cancer in the year after diagnosis, J Oncol Pract, 15, e20, 10.1200/JOP.18.00254 · DOI
- Jiang, 2021, US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples, Qual Life Res, 30, 803, 10.1007/s11136-020-02650-y · DOI
Cited by
Sorted by citations
Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood · doi:10.1182/blood.2024024582 · Cited by 79
Self-citation
Metadata
- Authors
- Lee, H. C., Ramasamy, K., Weisel, K., Abonour, R., Hardin, J. W., Rifkin, R. M., Ailawadhi, S., Terebelo, H. R., Durie, B. G. M., Tang, D., Joshi, P., Liu, L., Jou, Y.-M., Che, M., Hernandez, G., Narang, M., Toomey, K., Gasparetto, C., Wagner, L. I., & Jagannath, S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Oxford (GB)
- University Medical Center Hamburg-Eppendorf (DE)
- Indiana University School of Medicine (US)
- University of South Carolina (US)
- Rocky Mountain Cancer Centers (US)
- Mayo Clinic in Florida (US)
- Cedars-Sinai Medical Center (US)
- Bristol-Myers Squibb (United States) (US)
- Somerville Hospital (US)
- Duke Medical Center (US)
- Wake Forest University Health Sciences (US)
- Mount Sinai Hospital (US)
- Corresponding author
- Jagannath, Sundar
- ORCID
- Venue
- Clinical Lymphoma Myeloma and Leukemia
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 23
- Issue
- 2
- Pages
- 112-122
- ISSN
- 2152-2650 (ISSN-L)
- OpenAlex
- W4309929751
- Cited by
- 13
- References
- 2
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 3
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Lymphoma Myeloma & Leukemia (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- treatment patterns, overall survival, health-related quality of life, health care utilization, hospitalization, carfilzomib, pomalidomide, daratumumab, EQ-5D, FACT-G
- MeSH terms
- Adult, Antineoplastic Combined Chemotherapy Protocols, Delivery of Health Care, Dexamethasone, Humans, Multiple Myeloma, Prospective Studies, Quality of Life, Receptors, Antigen, T-Cell, Registries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
